Hemab Therapeutics Holdings, Inc.

COAG

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0002114044

SEC filings (opens in a new tab)

No open-market purchases or sales by Hemab Therapeutics Holdings, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $1.33B in total; Soros Fund Management is the only superinvestor holding it.

Key figures

Market capClose on Nov 10, 2026: $1.81B
Insider buysOpen market, last 90 days: 0
Insider sellsOpen market, last 90 days: 0
13F holdersQ2 2026, +56 vs. previous quarter: 56
13F valueReported value at the end of Q2 2026: $1.33B
Superinvestors holdingAt the end of Q2 2026: 1

Price chart

Chart by TradingView (opens in a new tab)

Financials

See financial statements

From SEC filings, in USD.

Revenue, Q2 FY2026: –; No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest: 3.31M; Shares sold short
Change: +144.2K; +4.6% vs. previous
Days to cover: 7.31; At average daily volume

Superinvestors holding COAG, Q2 2026

Go to the superinvestors tab

1 superinvestor reports holding Hemab Therapeutics Holdings, Inc. on Form 13F. Percentages are the stock's share of each portfolio.

Soros Fund Management

George Soros

<0.1%

Hemab Therapeutics Holdings, Inc.'s share of the portfolio

Shares: 25,000
Value: $918.3K

Latest insider trades

See all insider trades

Open-market purchases and sales by Hemab Therapeutics Holdings, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Jun 17, 2026 (view filing)6:24 PM ET	Jun 15-16	2 days	RA Capital Healthcare Fund LP and 3 others10% Owner	PPurchase	+67.7K	$24.97	+$1.69M	+1.1%6.44M after	2 lots
May 21, 2026 (view filing)4:20 PM ET	May 19-20	2 days	RA Capital Healthcare Fund LP and 3 others10% Owner	PPurchase	+4.80K	$24.96	+$119.8K	+0.1%6.38M after	2 lots
May 14, 2026 (view filing)5:21 PM ET	May 12	2 days	RA Capital Healthcare Fund LP and 3 others10% Owner	PPurchase	+6.39K	$24.90	+$159.0K	+0.1%6.37M after
May 11, 2026 (view filing)5:44 PM ET	May 7-11	4 days	RA Capital Healthcare Fund LP and 3 others10% Owner	PPurchase	+51.3K	$24.75	+$1.27M	+0.8%6.37M after	5 lots
May 6, 2026 (view filing)7:16 PM ET	May 4-6	2 days	RA Capital Healthcare Fund LP and 5 othersDirector, 10% Owner	PPurchase	+2.84M	$18.39	+$52.2M	+81.8%6.31M after	6 lots

Top 10 13F holders, Q2 2026

See all 56 holders

The largest institutional positions in Hemab Therapeutics Holdings, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding COAG in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
Ra Capital Management, L.P.	7,808,627	$286.8M	2.49%	+7,808,627	New
Novo Holdings A/S	4,180,550	$153.6M	8.95%	+4,180,550	New
FMR LLC	3,697,837	$135.8M	0.01%	+3,697,837	New
Capital International Investors	3,603,876	$132.4M	0.03%	+3,603,876	New
Deep Track Capital, LP	3,602,093	$132.3M	1.95%	+3,602,093	New
Siren, L.L.C.	2,086,834	$76.6M	1.56%	+2,086,834	New
Avoro Capital Advisors LLC	1,925,150	$70.7M	0.63%	+1,925,150	New
Bain Capital Life Sciences Investors, LLC	1,650,000	$60.6M	3.60%	+1,650,000	New
JPMorgan Chase & Co	1,152,420	$42.3M	0.00%	+1,152,420	New
Vanguard Capital Management LLC	780,758	$28.7M	0.00%	+780,758	New

Holders of 5% or more of COAG

See all 9 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Hemab Therapeutics Holdings, Inc..

Largest holders of COAG from 13D and 13G filings
Holder	Latest form	Stake	Change	First filed	Latest filing	Filing
Ra Capital Management, L.P.	13G	16.60%7.73M shares	New	May 11, 20261 filing	May 11, 2026	SEC
AI Den-Mab LLC	13D	10.40%4.88M shares	New	May 11, 20261 filing	May 11, 2026	SEC
FMR LLC	13G/A	10.40%4.87M shares	+2.50 ppfrom 7.90%	Aug 6, 20262 filings	Nov 6, 2026	SEC
Novo Holdings A/S	13G	9.00%4.18M shares	New	Aug 14, 20261 filing	Aug 14, 2026	SEC
Deep Track Capital, LP	13G	8.15%3.60M shares	New	May 8, 20261 filing	May 8, 2026	SEC